The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study.
 
Bob T. Li
Consulting or Advisory Role - Biosceptre International; Roche; Thermo Fisher Scientific
Research Funding - AstraZeneca (Inst); BioMed Valley Discoveries (Inst); GRAIL (Inst); Illumina (Inst); Roche/Genentech (Inst)
 
Filip Janku
Consulting or Advisory Role - Deciphera; Foundation Medicine; Guardant Health; Novartis; Sequenom; Trovagene
Research Funding - Agios; Astellas Pharma; Biocartis; BioMed Valley Discoveries; Deciphera; Foundation Medicine; Fujifilm; Novartis; Piqur; Plexxikon; Roche; Symphony Evolution; Trovagene
Other Relationship - Bio-Rad
 
Manish R. Patel
No Relationships to Disclose
 
Ryan J. Sullivan
No Relationships to Disclose
 
Keith Flaherty
Stock and Other Ownership Interests - Clovis Oncology; Loxo
Consulting or Advisory Role - Adaptimmune; Aeglea Biotherapeutics; Amgen; Asana Biosciences; Bristol-Myers Squibb; Clovis Oncology; Genentech; Lilly; Loxo; Merck; miRNA Therapeutics; Novartis; Oncoceutics; Roche; Sanofi; Tioma Therapeutics
Research Funding - Novartis; Sanofi
 
Elizabeth Iannotti Buchbinder
Employment - Biodesix (I); Smith & Nephew (I)
Consulting or Advisory Role - Checkmate Pharmaceuticals
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Merck
 
Mario E. Lacouture
No Relationships to Disclose
 
Anna M. Varghese
Consulting or Advisory Role - Cancer Genetics (I); Sequenom (I)
Research Funding - BioMed Valley Discoveries (Inst); Lilly (Inst); Verastem (Inst)
 
Deborah Jean Lee Wong
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - ARMO BioSciences; AstraZeneca/MedImmune; BioMed Valley Discoveries; Kura Oncology; Merck Serono; Merck Sharp & Dohme
 
Mario Sznol
Stock and Other Ownership Interests - Adaptive Biotechnologies; Amphivena; Intensity Therapeutics
Consulting or Advisory Role - Adaptimmune; Agonox; Alexion Pharmaceuticals; Amgen; Anaeropharma; Astellas Pharma; AstraZeneca/MedImmune; Biodesix; Bristol-Myers Squibb; Genentech/Roche; Immune Design; Immune Design; Inovio Pharmaceuticals; Janssen Oncology; Kyowa Hakko Kirin; Lilly; Lion Biotechnologies; Lycera; Merck Sharp & Dohme; Merus; Modulate Pharma; Nektar; Novartis; Omniox; pfizer; Prometheus; Seagen; Symphony Evolution; Theravance; Vaccinex
Other Relationship - AcademicCME; Clinical Care Options; Dava Oncology; Haymarket Media; Imedex; Physicans' Education Resource; Prime Oncology; Research to Practice; TRM Oncology; Vindico
 
Jeffrey Alan Sosman
Consulting or Advisory Role - Array BioPharma; Genentech; Merck
Research Funding - BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst)
 
Vicki Leigh Keedy
Employment - Zimmer BioMet (I)
Consulting or Advisory Role - Janssen Oncology; Karyopharm Therapeutics; Threshold Pharmaceuticals
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); eleison pharmaceuticals (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Janssen (Inst); Lilly (Inst); medpacto (Inst); pfizer (Inst); Plexxikon (Inst); Roche (Inst); Threshold Pharmaceuticals (Inst)
 
Andrea Wang-Gillam
Consulting or Advisory Role - Merrimack; Newlink Genetics; pfizer
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); CTI (Inst); EMD Serono (Inst); Halozyme (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst); OncoMed (Inst); pfizer (Inst); Plexxikon (Inst); Precision Therapeutics (Inst); Verastem (Inst)
 
Antoni Ribas
Stock and Other Ownership Interests - Arcus Ventures; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; Kite, a Gilead company
Consulting or Advisory Role - Amgen; Genentech/Roche; Merck; Novartis
 
Anthony W. Tolcher
Employment - START
Leadership - Symphony Evolution
Consulting or Advisory Role - Akebia Therapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Bayer Schering Pharma (Inst); Bicycle Therapeutics (Inst); Blend Therapeutics (Inst); Boehringer Ingelheim (Inst); Celator (Inst); Elekta (Inst); Endocyte (Inst); Genmab (Inst); Heron (Inst); Ignyta (Inst); Janssen (Inst); Johnson & Johnson (Inst); MEDIAN Technologies (Inst); Merus (Inst); Nanobiotix (Inst); New B Innovation (Inst); OncoMed (Inst); Pierre Fabre (Inst); Rigontec (Inst); Symphony Evolution (Inst); Upsher-Smith (Inst); Zymeworks (Inst)
Research Funding - AbbVie (Inst); ArQule (Inst); Asana Biosciences (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Cerulean Pharma (Inst); Dicerna (Inst); Endocyte (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Macrogenics (Inst); Otsuka (Inst); Pfizer (Inst); Plexxikon (Inst); TaiRx, Inc. (Inst)
 
Sapna Pradyuman Patel
Stock and Other Ownership Interests - Provectus
Honoraria - Dava Oncology; PCME, Rockpointe; PlatformQ Health
Consulting or Advisory Role - Amgen; Genentech/Roche
Speakers' Bureau - Bristol-Myers Squibb (Mexico); Merck
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Prometheus (Inst); Reata Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb (Mexico); Merck
 
Mary Laura Varterasian
Consulting or Advisory Role - BioMed Valley Discoveries; Takeda
 
Dean Welsch
Employment - BioMed Valley Discoveries
 
David Michael Hyman
Consulting or Advisory Role - Atara Biotherapeutics; Chugai Pharma; CytomX Therapeutics
Research Funding - AstraZeneca; Puma Biotechnology
 
Jeffrey R. Infante
Research Funding - Aileron Therapeutics (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Celldex (Inst); Celldex (Inst); eFFECTOR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Janssen Oncology (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche (Inst); Roche (Inst); Tesaro (Inst)